Clofazimine (Lamprene) is a phenazine derivative (Barry, Belton, Conalty, Denneny, Edward, O'Sullivan, Twomey, and Winder, 1957) which is active against mycobacteria (Vischer, I969) . It has been used in the treatment of leprosy for more than io years (Browne, I965a) and recently it has also been tried in different dermatological diseases including psoriasis and pyoderma gangrenosum (Gip and Stempa, I976) . A common side-effect is a reddish-brown discoloration of the skin (Browne, I965b) , and there have been reports of pigmentation of the conjunctiva (Browne, I965b, I969; Schultz, I972) and of the comea (Ohman and Wahlberg, 1975) , although such changes have also been denied (Imkamp, I968) . The possibility that clofazimine treatment in psoriatic patients causes corneal changes is discussed.
The study comprised i9 patients who were being given clofazimine as a treatment for psoriasis; their mean age was 45 years. The dose was usually 400 mg daily for one to two months. Ocular examinations covered visual acuity, slit-lamp microscopy (HaagStreit 900 slit lamp using X Io to i6 ocular) ophthalmoscopy, applanation tonometry, Goldmann perimetry, and colour vision tests. The first ocular examination was performed between two days and two months after the clofazimine therapy had ceased.
Two patients, Cases i and 2, showed obvious corneal changes.
CASE I
A 47-year-old man with psoriasis pustulosa w, as treated with clofazimine I00-400 mg daily for two months (total dose 20 g). The psoriatic lesions improved, but the skin show-ed a reddish-brown discoloration which lasted six months after the clofazimine therapy had stopped.
At the first ocular examination two days after the end of the treatment the visual acuity, visual fields, and colour vision were normal. Slit-lamp microscopy revealed several fine brownish, branched lines in the most superficial layers of both corneae (Fig. i) . Sometimes the border of the line was well marked, but at other times the brownish colour merged into the surrounding cornea. Using high magnification ( x I6 ocular) the lines showed a fine granular appearance. The changes were localized to the lower part of the cornea and there were no epithelial defects. No pigmentation was seen in the deeper layers of the cornea or in the conjunctiva. The lens and fundus were normal except for a very fine granular pigmentation scattered over both macular regions.
Repeated examinations during a one-year follow-up period showed a gradual decrease in the corneal changes. However, at the last examination, a few, very fine, brownish lines could still be seen in both corneae.
CASE 2
A 29-year-old woman with psoriasis pustulosa was treated with clofazimine 100-400 mg daily for two months (total dose 20 g). The psoriatic lesions improved. The patient noted a slight reddish-brown discoloration of the skin and small dry spots on the legs. The discoloration had disappeared two to three months after the end of the treatment but some of the dry spots still remained six months later.
At the first ocular examination two weeks after the end of the treatment the visual acuity, visual fields, and colour vision were normal. The slit-lamp microscopy revealed fine, brownish lines in the superficial layers of both corneae similar to those observed in Case I (Fig. 2) . The conjunctiva, the deeper corneal layers, the lens, and fundus were normal.
Two months later there was a slight regression of the corneal changes and six months later the corneal lines had disappeared.
Both these patients denied having used any other drugs, for example chloroquine or phenothiazine derivatives.
CASES 3, 4, 5, and 6 In four patients, aged 70, 45, 37, and 32 years, both comeae showed a very fine, brownish line horizontally placed across the lower half at the site for lid closure. Using high magnification the line appeared slightly granular; it resembled a common change in the cornea called the Hudson-Staehli line. Visual acuity, visual fields, and colour vision were normal. At examination six to eight months later the line could hardly be seen in one patient (aged 37) but was unchanged in the other three.
Among the I9 patients in this study were two with One patient had a brown pigmentation of the conjunctiva similar to a conjunctival naevus. The pigmentation of the conjunctiva was unaltered six months after the treatment had finished.
There were no severe side-effects. Some of the patients showed a marked reddish-brown staining of the skin. Three patients had erythrodermia, and a few complained of nausea and fatigue.
Discussion
There are several kinds of superficial lines in the cornea similar to those observed in the present study. The most common is the Hudson-Staehli line in which iron is deposited in the cornea (Gass, I964) . Corneal lines are also observed after exposure to certain substances, for example, atebrin, and are a well-known complication during treatment with chloroquine and its analogues. In certain corneal diseases there are brownish lines caused by deposition of melanin. The morphological resemblance and possible relationship between these changes are discussed by Bron (1973) .
In the present study microscopical examination of I9 psoriatic patients given clofazimine revealed bilateral corneal changes in six cases. Two patients showed between five and IO brownish, curved lines in the superficial part of both comeae. The changes resembled chloroquine keratopathy except for the brownish colour. None of the patients in this series had used any drugs known to cause corneal opacities nor had they any corneal disease.
The other four patients showed very slight changes, usually there was one brownish corneal line, which it was not possible to differentiate from a Hudson-Staehli line. This line is common in old people, but may be seen by the third and fourth decades (Gass, I964) . The Conjunctival pigmentation has been reported in some lepromatous patients during clofazimine therapy, but was not observed in our study.
There have been no reports oF corneal changes in lepromatous patients given clofazimine. The reason may be that the changes are minimal and seen only by microscopical examination. In a study by Imkamp (I968) , however, the patients were examined by slit lamp and yet no corneal opacities were found compared to the two cases found in our series. This difference could possibly be due to the fact that Imkamp's patients had been treated mainly with a lower daily dose of clofazimine (I 00 mg). 
